Capricor Therap (CAPR) Stock Price, Quote & News

Company Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial t...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 727 1755

Website: www.capricor.com

Address:

10865 Road to the Cure, Suite 150, San Diego, United States

nickiead Apr. 28 at 9:01 PM

$CAPR Makary says search has gone extremely well with some terrific candidates. His preference, according to several sources is Hemmati, so I expect he will get the position.

1 · Reply

UncleB13 Apr. 28 at 8:02 PM

$CAPR as I suspected

8 · Reply

Macme Apr. 28 at 7:35 PM

$CAPR Late spike? Let’s see

0 · Reply

bronx24bomber Apr. 28 at 7:04 PM

$CAPR This has gone from green to red in the last hour on multiple occasions. Lets hope we get the opposite today.

0 · Reply

WBinthehouse Apr. 28 at 6:58 PM

$CAPR The highest price ever paid for a Priority Review Voucher is $350 million. This record was set in 2015 when AbbVie purchased a Rare Pediatric Disease PRV from United Therapeutics. PRVs are FDA issued vouchers that allow a company to receive priority FDA review for a new drug application, and they can be sold or transferred to other companies. They are especially valuable for rare disease drugs or certain tropical disease treatments.

1 · Reply

wkee Apr. 28 at 6:42 PM

$CAPR get your popcorn !! 🍿

1 · Reply

Atmwireless Apr. 28 at 6:40 PM

$CAPR

0 · Reply

aricray Apr. 28 at 6:40 PM

$CAPR added

0 · Reply

ys95 Apr. 28 at 6:36 PM

$CAPR well looks like we are finally gonna hit the 3month trendline. Good news is, it now sits at $33.40ish. (It’s moved up a bunch these past couple of weeks) it would also be great if we only get close and not touch it. Time will tell.

0 · Reply

Marthvadir Apr. 28 at 6:32 PM

$CAPR Added 40

0 · Reply

Capricor Therapeutics Stock Slides As Q4 Earnings Miss Estimates

Mar 12, 2026, 4:30 PM EDT - 6 weeks ago

Capricor Therapeutics Earnings Call Transcript: Q4 2025

Mar 12, 2026, 4:01 PM EDT - 6 weeks ago

Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 12, 2026, 9:00 AM EDT - 6 weeks ago

Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy

Mar 10, 2026, 10:47 AM EDT - 7 weeks ago

Capricor Therapeutics Stock Jumps As FDA Resumes Deramiocel Review

Mar 10, 2026, 9:25 AM EDT - 7 weeks ago

Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA

Mar 9, 2026, 1:32 PM EDT - 7 weeks ago

What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday?

MRNA

Dec 17, 2025, 1:00 PM EST - 4 months ago

Capricor Therapeutics Transcript: Study Result

Dec 4, 2025, 4:01 PM EST - 5 months ago

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

Dec 3, 2025, 2:21 PM EST - 5 months ago

Capricor Stock Soars, Shkreli Is Short: Here's What Pharma Bro Had To Say

Dec 3, 2025, 11:30 AM EST - 5 months ago

Capricor Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 9:23 AM EST - 5 months ago

Capricor Therapeutics Duchenne Treatment Shows Strong Heart And Muscle Results In Trial

Dec 3, 2025, 8:00 AM EST - 5 months ago

Capricor Therapeutics Transcript: Status Update

Dec 3, 2025, 7:44 AM EST - 5 months ago

Capricor's muscle disorder cell therapy succeeds in late-stage study

Nov 24, 2025, 1:49 PM EST - 5 months ago

Martin Shkreli Takes Aim At Capricor — Stock Sinks

Nov 10, 2025, 4:30 PM EST - 6 months ago

Capricor Therapeutics Earnings Call Transcript: Q3 2025

Nov 3, 2025, 9:15 AM EST - 6 months ago

Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel

Oct 31, 2025, 9:15 AM EDT - 6 months ago

Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10

Oct 3, 2025, 10:45 AM EDT - 7 months ago

Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation

Sep 25, 2025, 8:30 AM EDT - 7 months ago

Capricor Therapeutics Transcript: Study Update

Sep 25, 2025, 7:15 AM EDT - 7 months ago

Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting

Sep 13, 2025, 11:35 AM EDT - 8 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Sep 9, 2025, 9:20 AM EDT - 8 months ago

Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel

Aug 28, 2025, 7:05 PM EDT - 8 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Aug 22, 2025, 10:20 AM EDT - 8 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Aug 11, 2025, 4:30 PM EDT - 9 months ago

Capricor Therapeutics Earnings Call Transcript: Q2 2025

Aug 8, 2025, 8:30 AM EDT - 9 months ago

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

Aug 6, 2025, 9:00 AM EDT - 9 months ago

Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13

Jul 31, 2025, 8:45 AM EDT - 9 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit - CAPR

Jul 30, 2025, 4:27 PM EDT - 9 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit – CAPR

Jul 30, 2025, 11:07 AM EDT - 9 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

SRPT CABA NGNE NTLA QURE RCKT

Jul 17, 2025, 4:46 PM EDT - 10 months ago

BREAKING: Capricor Therapeutics Sued For Securities Fraud; Investors Should Contact Block & Leviton to Potentially Recover Losses

Jul 16, 2025, 7:55 PM EDT - 10 months ago

Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Capricor Stockholders and Encourages Investors to Contact the Firm

Jul 14, 2025, 4:14 PM EDT - 10 months ago

Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors

Jul 11, 2025, 4:53 PM EDT - 10 months ago

Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura

Jul 11, 2025, 9:03 AM EDT - 10 months ago

Capricor's Lead Duchenne Therapy Hits FDA Regulatory Roadblock

Jul 11, 2025, 8:30 AM EDT - 10 months ago

Capricor Therapeutics Transcript: Study Update

May 13, 2025, 4:30 PM EDT - 1 year ago

Capricor Therapeutics Earnings Call Transcript: Q1 2025

Mar 19, 2025, 4:30 PM EDT - 1 year ago

Capricor Therapeutics Earnings Call Transcript: Q4 2024

Mar 12, 2025, 1:00 PM EDT - 1 year ago

Capricor Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Feb 12, 2025, 12:00 PM EST - 1 year ago

Capricor Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Dec 3, 2024, 11:30 AM EST - 1 year ago

Capricor Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 13, 2024, 4:30 PM EST - 1 year ago

Capricor Therapeutics Earnings Call Transcript: Q3 2024

Sep 24, 2024, 8:30 AM EDT - 1 year ago

Capricor Therapeutics Transcript: Study Update

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Capricor Therapeutics Earnings Call Transcript: Q2 2024

May 13, 2024, 4:30 PM EDT - 2 years ago

Capricor Therapeutics Earnings Call Transcript: Q1 2024

Apr 29, 2024, 8:30 AM EDT - 2 years ago

Capricor Therapeutics Transcript: FDA Announcement

Feb 29, 2024, 4:30 PM EST - 2 years ago

Capricor Therapeutics Earnings Call Transcript: Q4 2023

Nov 14, 2023, 4:30 PM EST - 2 years ago

Capricor Therapeutics Earnings Call Transcript: Q3 2023

Sep 29, 2023, 8:30 AM EDT - 2 years ago

Capricor Therapeutics Transcript: FDA Announcement

Aug 7, 2023, 4:30 PM EDT - 2 years ago

Capricor Therapeutics Earnings Call Transcript: Q2 2023

May 11, 2023, 4:30 PM EDT - 3 years ago

Capricor Therapeutics Earnings Call Transcript: Q1 2023

Mar 15, 2023, 4:30 PM EDT - 3 years ago

Capricor Therapeutics Earnings Call Transcript: Q4 2022

Nov 10, 2022, 1:30 PM EST - 3 years ago

Capricor Therapeutics Earnings Call Transcript: Q3 2022

Aug 10, 2022, 11:30 AM EDT - 4 years ago

Capricor Therapeutics Earnings Call Transcript: Q2 2022

May 10, 2022, 8:39 AM EDT - 4 years ago

Capricor Therapeutics Earnings Call Transcript: Q1 2022

Mar 10, 2022, 5:45 AM EST - 4 years ago

Capricor Therapeutics Earnings Call Transcript: Q4 2021

Nov 9, 2021, 10:20 AM EST - 4 years ago

Capricor Therapeutics Earnings Call Transcript: Q3 2021

Aug 12, 2021, 11:58 AM EDT - 5 years ago

Capricor Therapeutics Earnings Call Transcript: Q2 2021

May 13, 2021, 11:27 AM EDT - 5 years ago

Capricor Therapeutics Earnings Call Transcript: Q1 2021

nickiead Apr. 28 at 9:01 PM

$CAPR Makary says search has gone extremely well with some terrific candidates. His preference, according to several sources is Hemmati, so I expect he will get the position.

1 · Reply

UncleB13 Apr. 28 at 8:02 PM

$CAPR as I suspected

8 · Reply

Macme Apr. 28 at 7:35 PM

$CAPR Late spike? Let’s see

0 · Reply

bronx24bomber Apr. 28 at 7:04 PM

$CAPR This has gone from green to red in the last hour on multiple occasions. Lets hope we get the opposite today.

0 · Reply

WBinthehouse Apr. 28 at 6:58 PM

1 · Reply

wkee Apr. 28 at 6:42 PM

$CAPR get your popcorn !! 🍿

1 · Reply

Atmwireless Apr. 28 at 6:40 PM

$CAPR

0 · Reply

aricray Apr. 28 at 6:40 PM

$CAPR added

0 · Reply

ys95 Apr. 28 at 6:36 PM

0 · Reply

Marthvadir Apr. 28 at 6:32 PM

$CAPR Added 40

0 · Reply

Stonksgoingup Apr. 28 at 6:12 PM

$CAPR

0 · Reply

Bentradez Apr. 28 at 6:05 PM

$CAPR following the market until we hear something new. Just holding and excited to see what’s to come 🍪

0 · Reply

patatechaude Apr. 28 at 3:25 PM

$CAPR The news we're actually waiting for is "approval". And it's closer by the day. May?

1 · Reply

Fidusen Apr. 28 at 3:14 PM

$CAPR looks like another 35 day - not for long though

0 · Reply

wkee Apr. 28 at 3:00 PM

$CAPR 80.00 with fda news of new guy!!! Let's go Linda !!

2 · Reply

crestycrust Apr. 28 at 2:54 PM

$CAPR I wonder if the vetting process is taking a while with the new guy having private industry experience. If that’s the case we may see an interim announced Friday.

1 · Reply

WBinthehouse Apr. 28 at 2:53 PM

$CAPR @oneg a year old article about Oppenheimer with a $22 price target PPS when it was $6 has since been revised. As of early 2026, Oppenheimer analyst Leland Gershell maintains an Outperform rating on Capricor Therapeutics (CAPR) with a price target of $54.00.

1 · Reply

ODLH Apr. 28 at 2:51 PM

$CAPR Gemini suggested to take the replacement as a non-event, because people normally reject such an offer when they can find one at a corporate, it is low pay and boring. So probably Hemmati doesn’t even want to take it, someone will be named as an interim leader before they finally find one. OK, let’s wait for this closet peeker to fuck off and maybe Nicole comes back on 5/1?

2 · Reply

dnfrs Apr. 28 at 2:31 PM

$CAPR The new appointment will be announced by the government, not Capricor. It can come any time , any day . I would want to be all in when that announcement is made. And I am.

0 · Reply

oneg Apr. 28 at 2:18 PM

$CAPR Is FDA approval already fully priced in? If they receive less than 34% of total sales, is there any meaningful upside remaining? https://www.streetwisereports.com/article/2025/09/26/biotech-discovers-breakthrough-dmd-therapy-opportunity.html

5 · Reply

wkee Apr. 28 at 2:04 PM

$CAPR news coming for sure!!!

2 · Reply

WBinthehouse Apr. 28 at 2:04 PM

$CAPR Deramiocel has all the numbers pegged. The FDA is not going to say hey they are all stat sig but blah blah blah blah bla blah. lol Nah! Willis ain’t crazy! Slam dunk! Foregone conclusion an accomplished fact.

0 · Reply

Market Cap	2.04B
Revenue (ttm)	0.00
Net Income (ttm)	-105.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	4,063.20
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	756,612
Avg Vol	1,326,642
Day's Range	N/A - N/A
Shares Out	57.84M
Stochastic %K	61%
Beta	0.48
Analysts	Strong Sell
Price Target	$54.67